E2 Supp Care II Flashcards
list the shit for OPQRSTU
onset
provokes
quality
radiate
severe
time
understanding
which opioid has the most “familiarity” in cancer
morphine
morphine metabolized where
liver
morphine metabolites excreted where
kidney
hydromorphone metabolized where
liver
t or f:
both morphine and hydromorphone should be used with caution in liver dysfxn
true
what metabolizes oxycodone?
CYP2D6
Use oxycodone with caution in pts with?
liver dysfxn
which opioids appears to be safe in renal dysfxn?
fentanyl
methadone
which opioid is a good alternative for pts with head/neck/esophageal cancer who may not be able to maintain adequate PO intake?
fentanyl
which opioid has REMS protocol
fentanyl
which opioid to use in pts with true morphine allergy
methadone
opioid to use in pts with neuropathic pain
methadone
methadone metabolites excreted where?
urine and feces
Methadone not advised in what dysfxn
liver
which opioid has risk of QTC prolongation
methadone
what is something you always add when opioid tx is initiated
bowel regimen (mild stim lax +/- stool softener
4 common tox of opioids
constipation
sedation
N/V
pruritus
opioid common tox tx:
sedation
tolerance within few days
hold sedatives/anxiolytics
reduce dose
opioid common tox tx:
N/V
change opioid
add scheduled anti-emesis tx
Pruritus is most often seen with _________ administration
morphine
what common opioid toxicity are we able to give a low dose of naloxone for?
respiratory depression
Patient Controlled Analgesia (PCA):
Use caution with continuous basal dosing initially for _________ _______ patients
opioid naïve
what is the celiac plexus
a group of nerves that supply organs in the abdomen
go look at slide 34 and try to see what you can gather from step 3
okay i will do this, cole
Used in patients who are refractory to other opioid therapy or increased toxicities (not a drug)
intrathecal pain pumps
T or F:
Patients generally have more toxicities from intrathecal pain pumps than benefit from traditional opioid therapy
true
RECIST
Response
Evaluation
Criteria
In
Solid
Tumors
RECIST Criteria:
Disappearance of all target lesions
A. Complete response (CR)
B. Partial response (PR)
C. Progressive disease (PD)
D. Stable disease (SD)
A
RECIST Criteria:
30% decrease in the sum of the longest diameter of target lesions
A. Complete response (CR)
B. Partial response (PR)
C. Progressive disease (PD)
D. Stable disease (SD)
B
RECIST Criteria:
20% increase in the sum of the longest diameter of target lesions
A. Complete response (CR)
B. Partial response (PR)
C. Progressive disease (PD)
D. Stable disease (SD)
C
RECIST Criteria:
Small changes that don’t meet above criteria
A. Complete response (CR)
B. Partial response (PR)
C. Progressive disease (PD)
D. Stable disease (SD)
D
